Browse the evidence

Pomegranate-derived phytochemicals, specifically anthocyanins (ATs) and urolithins (metabolites of hydrolyzable tannins), exhibit anti-cancer and cardioprotective bioactivities through mechanisms including aromatase inhibition, apoptosis induction, and oxidative stress reduction.

This paper reviews laboratory and animal studies showing that compounds in pomegranate (like anthocyanins and urolithins) can inhibit cancer cell growth and support heart health in controlled settings. However, it explicitly notes that these findings have not been confirmed in human clinical trials. Do not use pomegranate supplements as a treatment for cancer or heart disease without consulting a physician, as the clinical efficacy and dosage protocols for humans are not established.

Higher abundance of Dysosmobacter welbionis in the human gut is negatively correlated with Body Mass Index (BMI), fasting glucose, and glycated hemoglobin (HbA1c) in obese individuals with metabolic syndrome.

In humans with obesity and metabolic syndrome, higher levels of Dysosmobacter welbionis in the gut are associated with lower BMI, better blood sugar control, and lower HbA1c. This suggests that maintaining or increasing this bacterium may be beneficial for metabolic health.

Hesperidin reduces obesity and lipid accumulation by activating AMPK and PPAR signaling pathways, which regulates lipid and glucose metabolism, while simultaneously reducing inflammation via NF-κB inhibition and oxidative stress.

This paper reviews how hesperidin, a compound found in citrus fruits, may help with obesity in animal studies by improving how the body handles fat and sugar. However, it explicitly states that human clinical trials are lacking. Therefore, you cannot currently rely on hesperidin supplements for weight loss based on this evidence alone; more research is needed to establish safe and effective human dosing.

Time-Restricted Feeding (TRF) shows profound metabolic benefits in rodents (improved glucose tolerance, reduced adiposity/steatosis) even without energy restriction, but human studies are sparse, mixed, and methodologically limited, with some showing worsened glycaemia.

If you try Time-Restricted Feeding (TRF), limit your eating window to 10-12 hours daily. Be aware that human evidence is mixed; some studies show worsened glycaemia, possibly due to timing (e.g., evening eating) or methodological issues. Monitor your blood glucose and lipids, and consider experimenting with earlier eating windows if possible, as this may align better with circadian biology.

Weight loss interventions in overweight and obese men do not show consistent or significant improvements in fertility outcomes due to a lack of high-quality randomized studies.

For overweight or obese men seeking to improve fertility, current evidence is insufficient to recommend specific weight loss protocols, though general health benefits apply. More research is needed.

Exercise induces a phenotypic switch in white adipose tissue (WAT) to thermogenic 'beige' adipocytes via multiple mechanisms including myokine secretion (irisin, IL-6, meteorin-like), natriuretic peptides, and angiogenesis, although the metabolic benefit and necessity of this process in humans remain uncertain.

Exercise likely triggers biological changes in fat tissue (browning) in animals, but this hasn't been proven to happen or help in humans. Don't rely on 'browning' as a weight loss strategy; focus on the proven benefits of exercise like improved insulin sensitivity and cardiovascular health.

Intermittent Fasting (IF) in normal-weight subjects may cause adverse metabolic effects, including increased visceral fat, muscle insulin resistance, and increased intramyocellular triglycerides, which are not seen with Intermittent Energy Restriction (IER) or Continuous Energy Restriction (CER).

If you are already lean, avoid total fasting (0 calories). It may cause your body to store fat in your muscles and liver, worsening insulin sensitivity. Stick to partial restriction (eating some food) if you want to try intermittent fasting.

Asprosin promotes hepatic glucose production (gluconeogenesis) and stimulates appetite (orexigenic effect) via central and peripheral signaling pathways, although the reproducibility of these effects is controversial due to reagent quality issues.

Research suggests asprosin might increase hunger and liver glucose output, but studies are inconsistent. Some early positive findings may have been due to experimental errors. Until the science is settled, focus on proven methods for managing hunger and blood sugar like balanced nutrition and exercise.

Asprosin may have a protective role in cardiovascular disease by preventing cardiomyocyte apoptosis and improving mesenchymal stromal cell function in myocardial infarction models.

Current research indicates asprosin might protect heart cells from damage in diabetic conditions and improve stem cell therapy outcomes for heart attacks. However, this is still in early research stages. For now, managing cardiovascular risk factors remains the standard of care.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.

There is no single 'best' combination therapy yet. The field is still debating whether to maximize GLP-1, add glucagon, or add GIP. Current trials are testing different ratios (e.g., 1:1 vs 5:1 GLP-1:glucagon). Patients should expect that these therapies are evolving and that side effects (nausea, hyperglycemia) may limit the dose that can be tolerated.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

Beta-amyrin acetate, a compound derived from the medicinal fungus Poria cocos, acts as a putative antagonist of the Neuropeptide Y1 receptor (Y1R) by binding to the orthosteric site with high affinity, potentially inhibiting feeding behavior associated with obesity.

Beta-amyrin acetate is a specific chemical compound found in the fungus Poria cocos. Current research is purely computational (computer simulations), predicting it might block a specific brain receptor (Y1R) involved in hunger. There is no human dosing protocol or clinical evidence yet; do not use this as a weight loss treatment based on this paper alone.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.

This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.

Combination therapy of the LPAR1 antagonist EPGN2154 and the GLP-1 agonist Semaglutide results in the maximum body weight loss and fat mass reduction in diet-induced obese mice, outperforming either drug alone.

Combining a GLP-1 agonist (like Semaglutide) with an LPAR1 antagonist (like EPGN2154) appears to maximize weight loss in preclinical models, potentially offering a synergistic effect for obesity management.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

Obesity-associated DNA damage in germ cells (sperm and oocytes) can be transmitted to offspring, potentially causing de novo mutations and affecting the health of future generations.

If you are obese and planning to have children, your current health status can impact your child's genetic health. Obesity can cause DNA damage in sperm and eggs, which may lead to mutations or metabolic issues in the child. Preconception weight management and healthy lifestyle choices can help reduce these risks for your future offspring.

Exercise-induced browning of subcutaneous white adipose tissue (ScAT) in rodents may serve as an adaptive mechanism to compensate for reduced insulation due to fat loss or to manage oxidative stress/redox state, rather than primarily for thermogenesis.

In animals, fat tissue changes during exercise might be a response to stress or inflammation rather than just burning calories. This doesn't change the advice: keep exercising for overall health, as the specific 'browning' mechanism is not proven to help humans lose weight.

Once-weekly subcutaneous semaglutide 2.4 mg produces clinically significant, sustained weight loss (mean -10.2% at 208 weeks) in adults with preexisting cardiovascular disease and obesity/overweight without diabetes, compared to placebo.

If you have heart disease and are overweight or obese (even without diabetes), once-weekly semaglutide 2.4 mg can help you lose about 10% of your body weight over 4 years, which is significantly more than placebo. This benefit is seen across different sexes, races, and BMI categories, though those with lower starting BMI might stop the medication more often due to side effects or lack of motivation. The key is that it works sustainably for cardiovascular health.

Semaglutide (2.4 mg/week) induces significant weight loss (mean -10.09% body weight) and improves cardiometabolic markers (BMI, waist circumference, blood pressure, CRP, lipids) in obese or overweight non-diabetic adults, with efficacy increasing with dose.

For non-diabetic adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, averaging a 10% reduction in body weight. It also improves blood pressure, inflammation (CRP), and lipid profiles. While gastrointestinal side effects like nausea are common, they are typically transient. The treatment is dose-dependent, with higher doses yielding greater weight loss.